Skip to main content

01.12.2021 | Original Article

Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET/CT features

verfasst von: F. Montes de Jesus, Y. Yin, E. Mantzorou-Kyriaki, X. U. Kahle, R. J. de Haas, D. Yakar, A. W. J. M. Glaudemans, W. Noordzij, T. C. Kwee, M. Nijland

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

One of the challenges in the management of patients with follicular lymphoma (FL) is the identification of individuals with histological transformation, most commonly into diffuse large B-cell lymphoma (DLBCL). [18F]FDG-PET/CT is used for staging of patients with lymphoma, but visual interpretation cannot reliably discern FL from DLBCL. This study evaluated whether radiomic features extracted from clinical baseline [18F]FDG PET/CT and analyzed by machine learning algorithms may help discriminate FL from DLBCL.

Materials and methods

Patients were selected based on confirmed histopathological diagnosis of primary FL (n=44) or DLBCL (n=76) and available [18F]FDG PET/CT with EARL reconstruction parameters within 6 months of diagnosis. Radiomic features were extracted from the volume of interest on co-registered [18F]FDG PET and CT images. Analysis of selected radiomic features was performed with machine learning classifiers based on logistic regression and tree-based ensemble classifiers (AdaBoosting, Gradient Boosting, and XG Boosting). The performance of radiomic features was compared with a SUVmax-based logistic regression model.

Results

From the segmented lesions, 121 FL and 227 DLBCL lesions were included for radiomic feature extraction. In total, 79 radiomic features were extracted from the SUVmap, 51 from CT, and 6 shape features. Machine learning classifier Gradient Boosting achieved the best discrimination performance using 136 radiomic features (AUC of 0.86 and accuracy of 80%). SUVmax-based logistic regression model achieved an AUC of 0.79 and an accuracy of 70%. Gradient Boosting classifier had a significantly greater AUC and accuracy compared to the SUVmax-based logistic regression (p≤0.01).

Conclusion

Machine learning analysis of radiomic features may be of diagnostic value for discriminating FL from DLBCL tumor lesions, beyond that of the SUVmax alone.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed Non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:5165–9.CrossRef Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed Non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:5165–9.CrossRef
2.
Zurück zum Zitat Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PMV, Stathis A, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157:188–96.CrossRef Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PMV, Stathis A, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157:188–96.CrossRef
3.
Zurück zum Zitat Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. American Society of Hematology. 2019;134:761–4. Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. American Society of Hematology. 2019;134:761–4.
4.
Zurück zum Zitat Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. American Society of Clinical Oncology. 2015;33:2516–22.CrossRef Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. American Society of Clinical Oncology. 2015;33:2516–22.CrossRef
5.
Zurück zum Zitat Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426–33.CrossRef Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426–33.CrossRef
6.
Zurück zum Zitat Link BK, Maurer MJ, Nowakowski GS, Ansell SM, MacOn WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of Iowa/mayo clinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31:3272–8.CrossRef Link BK, Maurer MJ, Nowakowski GS, Ansell SM, MacOn WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of Iowa/mayo clinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31:3272–8.CrossRef
7.
Zurück zum Zitat Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575–82.CrossRef Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575–82.CrossRef
8.
Zurück zum Zitat Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the national LymphoCare study (NLCS). Blood. 2015;126:851–7.CrossRef Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the national LymphoCare study (NLCS). Blood. 2015;126:851–7.CrossRef
9.
Zurück zum Zitat Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. Elsevier Ltd.; 2021;32:298–308. Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. Elsevier Ltd.; 2021;32:298–308.
10.
Zurück zum Zitat Papajík T, Mysliveček M, Šedová Z, Buriánková E, Procházka V, Koranda P, et al. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin’s lymphoma. Eur J Haematol. 2011;86:32–7.CrossRef Papajík T, Mysliveček M, Šedová Z, Buriánková E, Procházka V, Koranda P, et al. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin’s lymphoma. Eur J Haematol. 2011;86:32–7.CrossRef
11.
Zurück zum Zitat Novelli S, Briones J, Flotats A, Sierra J. PET/CT assessment of follicular lymphoma and high grade B cell lymphoma - good correlation with clinical and histological features at diagnosis. Adv Clin Exp Med. 2015;24:325–30.CrossRef Novelli S, Briones J, Flotats A, Sierra J. PET/CT assessment of follicular lymphoma and high grade B cell lymphoma - good correlation with clinical and histological features at diagnosis. Adv Clin Exp Med. 2015;24:325–30.CrossRef
12.
Zurück zum Zitat Mir F, Barrington SF, Brown H, Nielsen T, Sahin D, Meignan M, et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood. 2020;135:1214–8.CrossRef Mir F, Barrington SF, Brown H, Nielsen T, Sahin D, Meignan M, et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood. 2020;135:1214–8.CrossRef
13.
Zurück zum Zitat Noy A, Schöder H, Gönen M, Weissler M, Ertelt K, Cohler C, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20:508–12.CrossRef Noy A, Schöder H, Gönen M, Weissler M, Ertelt K, Cohler C, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20:508–12.CrossRef
14.
Zurück zum Zitat Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they Are data. Radiology. 2016;278:563–77.CrossRef Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they Are data. Radiology. 2016;278:563–77.CrossRef
15.
Zurück zum Zitat Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53:1041–7.CrossRef Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53:1041–7.CrossRef
16.
Zurück zum Zitat Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.CrossRef Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.CrossRef
17.
Zurück zum Zitat Koçak B, Durmaz EŞ, Ateş E, Kılıçkesmez Ö. Radiomics with artificial intelligence: a practical guide for beginners. Diagnostic Interv Radiol. 2019;25:485–95.CrossRef Koçak B, Durmaz EŞ, Ateş E, Kılıçkesmez Ö. Radiomics with artificial intelligence: a practical guide for beginners. Diagnostic Interv Radiol. 2019;25:485–95.CrossRef
18.
Zurück zum Zitat Wang H, Zhou Y, Li L, Hou W, Ma X, Tian R. Current status and quality of radiomics studies in lymphoma: a systematic review. Eur Radiol. 2020;30:6228–40.CrossRef Wang H, Zhou Y, Li L, Hou W, Ma X, Tian R. Current status and quality of radiomics studies in lymphoma: a systematic review. Eur Radiol. 2020;30:6228–40.CrossRef
19.
Zurück zum Zitat Lippi M, Gianotti S, Fama A, Casali M, Barbolini E, Ferrari A, et al. Texture analysis and multiple-instance learning for the classification of malignant lymphomas. Comput Methods Programs Biomed. Elsevier B.V.; 2020;185:105153. Lippi M, Gianotti S, Fama A, Casali M, Barbolini E, Ferrari A, et al. Texture analysis and multiple-instance learning for the classification of malignant lymphomas. Comput Methods Programs Biomed. Elsevier B.V.; 2020;185:105153.
20.
Zurück zum Zitat Lartizien C, Rogez M, Niaf E, Ricard F. Computer-aided staging of lymphoma patients with FDG PET/CT imaging based on textural information. IEEE J Biomed Heal Informatics. IEEE. 2014;18:946–55.CrossRef Lartizien C, Rogez M, Niaf E, Ricard F. Computer-aided staging of lymphoma patients with FDG PET/CT imaging based on textural information. IEEE J Biomed Heal Informatics. IEEE. 2014;18:946–55.CrossRef
21.
Zurück zum Zitat Zhou Y, Ma X-L, Pu L-T, Zhou R-F, Ou X-J, Tian R. Prediction of overall survival and progression-free survival by the 18 F-FDG PET/CT radiomic features in patients with primary gastric diffuse large B-cell lymphoma. Contrast Media Mol Imaging. 2019;2019:1–9.CrossRef Zhou Y, Ma X-L, Pu L-T, Zhou R-F, Ou X-J, Tian R. Prediction of overall survival and progression-free survival by the 18 F-FDG PET/CT radiomic features in patients with primary gastric diffuse large B-cell lymphoma. Contrast Media Mol Imaging. 2019;2019:1–9.CrossRef
22.
Zurück zum Zitat Lue K-H, Wu Y-F, Liu S-H, Hsieh T-C, Chuang K-S, Lin H-H, et al. Intratumor heterogeneity assessed by 18F-FDG PET/CT predicts treatment response and survival outcomes in patients with Hodgkin lymphoma. Acad Radiol. 2020;27:e183–92.CrossRef Lue K-H, Wu Y-F, Liu S-H, Hsieh T-C, Chuang K-S, Lin H-H, et al. Intratumor heterogeneity assessed by 18F-FDG PET/CT predicts treatment response and survival outcomes in patients with Hodgkin lymphoma. Acad Radiol. 2020;27:e183–92.CrossRef
23.
Zurück zum Zitat Mayerhoefer ME, Riedl CC, Kumar A, Gibbs P, Weber M, Tal I, et al. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging. 2019;46:2760–9.CrossRef Mayerhoefer ME, Riedl CC, Kumar A, Gibbs P, Weber M, Tal I, et al. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging. 2019;46:2760–9.CrossRef
24.
Zurück zum Zitat Boellaard R, Tatsch K, Pike LC, Testanera G, Kotzerke J, Graham MM, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. Boellaard R, Tatsch K, Pike LC, Testanera G, Kotzerke J, Graham MM, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
25.
Zurück zum Zitat Boellaard R, Oyen WJG, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.CrossRef Boellaard R, Oyen WJG, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.CrossRef
26.
Zurück zum Zitat Boellaard R, Willemsen A, Arends B, Visser EP. EARL procedure for assessing PET/CT system specific patient FDG activity preparations for quantitative FDG PET/CT studies. April. 2013;2010:1–3. Boellaard R, Willemsen A, Arends B, Visser EP. EARL procedure for assessing PET/CT system specific patient FDG activity preparations for quantitative FDG PET/CT studies. April. 2013;2010:1–3.
27.
Zurück zum Zitat Pfaehler E, van Sluis J, Merema BBJ, van Ooijen P, Berendsen RCM, van Velden FHP, et al. Experimental multicenter and multivendor evaluation of the performance of PET radiomic features using 3-dimensionally printed phantom inserts. J Nucl Med. 2020;61:469–76.CrossRef Pfaehler E, van Sluis J, Merema BBJ, van Ooijen P, Berendsen RCM, van Velden FHP, et al. Experimental multicenter and multivendor evaluation of the performance of PET radiomic features using 3-dimensionally printed phantom inserts. J Nucl Med. 2020;61:469–76.CrossRef
28.
Zurück zum Zitat Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.CrossRef Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.CrossRef
29.
Zurück zum Zitat Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328–38.CrossRef Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328–38.CrossRef
30.
Zurück zum Zitat Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328–38.CrossRef Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328–38.CrossRef
31.
Zurück zum Zitat van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7.CrossRef van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7.CrossRef
32.
Zurück zum Zitat Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825–30. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825–30.
33.
Zurück zum Zitat Schapire RE. Explaining AdaBoost. Empir Inference. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. p. 37–52. Schapire RE. Explaining AdaBoost. Empir Inference. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. p. 37–52.
34.
Zurück zum Zitat Friedman JH. Greedy function approximation: a gradient boosting machine. Ann Stat. 2001;29. Friedman JH. Greedy function approximation: a gradient boosting machine. Ann Stat. 2001;29.
35.
Zurück zum Zitat Chen T, Guestrin C. XGBoost. Proc 22nd ACM SIGKDD Int Conf Knowl Discov Data Min. New York, NY, USA: ACM; 2016. p. 785–94. Chen T, Guestrin C. XGBoost. Proc 22nd ACM SIGKDD Int Conf Knowl Discov Data Min. New York, NY, USA: ACM; 2016. p. 785–94.
36.
Zurück zum Zitat Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.CrossRef Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.CrossRef
37.
Zurück zum Zitat Ngeow JYY, Quek RHH, Ng DCE, Hee SW, Tao M, Lim LC, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol. 2009;20:1543–7.CrossRef Ngeow JYY, Quek RHH, Ng DCE, Hee SW, Tao M, Lim LC, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol. 2009;20:1543–7.CrossRef
38.
Zurück zum Zitat Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–51.CrossRef Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–51.CrossRef
39.
Zurück zum Zitat Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med. 1995;36:1790–6.PubMed Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med. 1995;36:1790–6.PubMed
40.
Zurück zum Zitat Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Söderström KO, et al. Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995;86:3522–7.CrossRef Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Söderström KO, et al. Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995;86:3522–7.CrossRef
41.
Zurück zum Zitat Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, et al. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. 2020;105:1907–13.CrossRef Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, et al. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. 2020;105:1907–13.CrossRef
42.
Zurück zum Zitat Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93:471–2.CrossRef Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93:471–2.CrossRef
43.
Zurück zum Zitat Karam M, Feustel PJ, Vera CD, Nazeer T. Features of large cell transformation of indolent lymphomas as observed on sequential PET/CT. Nucl Med Commun. 2011;32:177–85.CrossRef Karam M, Feustel PJ, Vera CD, Nazeer T. Features of large cell transformation of indolent lymphomas as observed on sequential PET/CT. Nucl Med Commun. 2011;32:177–85.CrossRef
44.
Zurück zum Zitat Wu X, Pertovaara H, Korkola P, Dastidar P, Järvenpää R, Eskola H, et al. Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma. PLoS One. 2014;9:e84999.CrossRef Wu X, Pertovaara H, Korkola P, Dastidar P, Järvenpää R, Eskola H, et al. Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma. PLoS One. 2014;9:e84999.CrossRef
45.
Zurück zum Zitat Mayerhoefer ME, Materka A, Langs G, Häggström I, Szczypiński P, Gibbs P, et al. Introduction to radiomics. J Nucl Med. 2020;61:488–95.CrossRef Mayerhoefer ME, Materka A, Langs G, Häggström I, Szczypiński P, Gibbs P, et al. Introduction to radiomics. J Nucl Med. 2020;61:488–95.CrossRef
46.
Zurück zum Zitat Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp. 2018;2. Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp. 2018;2.
47.
Zurück zum Zitat Ha S, Choi H, Paeng JC, Cheon GJ. Radiomics in oncological PET/CT: a methodological overview. Nucl Med Mol Imaging (2010). 2019;53:14–29. Ha S, Choi H, Paeng JC, Cheon GJ. Radiomics in oncological PET/CT: a methodological overview. Nucl Med Mol Imaging (2010). 2019;53:14–29.
48.
Zurück zum Zitat Mayerhoefer ME, Riedl CC, Kumar A, Dogan A, Gibbs P, Weber M, et al. Marrow involvement in mantle cell lymphoma : a retrospective study in 97 patients. Cancers (Basel). 2020;1–13. Mayerhoefer ME, Riedl CC, Kumar A, Dogan A, Gibbs P, Weber M, et al. Marrow involvement in mantle cell lymphoma : a retrospective study in 97 patients. Cancers (Basel). 2020;1–13.
49.
Zurück zum Zitat Zhang M, Bao Y, Rui W, Shangguan C, Liu J, Xu J, et al. Performance of 18F-FDG PET/CT radiomics for predicting EGFR mutation status in patients with Non-small cell lung cancer. Front Oncol. 2020;10:1–8.CrossRef Zhang M, Bao Y, Rui W, Shangguan C, Liu J, Xu J, et al. Performance of 18F-FDG PET/CT radiomics for predicting EGFR mutation status in patients with Non-small cell lung cancer. Front Oncol. 2020;10:1–8.CrossRef
Metadaten
Titel
Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET/CT features
verfasst von
F. Montes de Jesus
Y. Yin
E. Mantzorou-Kyriaki
X. U. Kahle
R. J. de Haas
D. Yakar
A. W. J. M. Glaudemans
W. Noordzij
T. C. Kwee
M. Nijland
Publikationsdatum
01.12.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-021-05626-3